Bicyclic PKM2 activators

Patent metadata

Field	Value
Publication number	US-9328077-B2
Application number	US-201113996286-A
Country	US
Kind code	B2
Filing date	Dec 21, 2011
Priority date	Dec 21, 2010
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

Compounds and compositions comprising compounds that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.

First claim

What is claimed is:

1. A compound of formula (I),

or a pharmaceutically acceptable salt thereof, wherein:
X and Y are each independently selected from O and N(-L-R 1 ), wherein X is O and Y is N(-L-R 1 ) or X is N(-L-R 1 ) and Y is O;
Q is C(O), SO 2 , or —(CH 2 ) h —;
each L is independently selected from a bond, —C(O)—, —(CR a R b ) m —, —C(O)N(R c )— or —C(O)O—;
D and D 1 are each independently selected from a bond, O and N(R c ), provided that D and D 1 are not both a bond;
A is aryl or heteroaryl, each of which is substituted with 0-3 occurrences of R d ; and D-Q-D 1 -A is not OCH 2 -phenyl;
each R 1 is independently selected from hydrogen, C 1-4 alkyl, halo C 1-4 alkyl, alkyl-O-alkylene, C 3-10 cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein each alkyl-O-alkylene, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl is substituted with 0-3 occurrences of R f and each alkyl and haloalkyl is substituted with 0-3 occurrences of R g ;
each R a and each R b are independently selected from hydrogen, C 1-4 alkyl, or R a and R b bound to the same carbon atom are taken together with the carbon atom to form a cycloalkyl;
each R c is independently selected from hydrogen and C 1-4 alkyl;
each R d is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, nitro, cyano, —OH and —O(C 1-4 alkyl), or two R d , attached to the same or adjacent carbon atoms, taken together with the atom(s) to which they are attached form an optionally substituted heterocyclyl;
each R f is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, nitro, cyano, —OH and —O(C 1-4 alkyl), or two R f , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R g is independently selected from nitro, cyano, —OH, —O(C 1-4 alkyl) or two R g , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R 2 is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy and hydroxyl;
h is 1, 2 or 3;
each m is independently 1, 2 or 3; and
each n is independently 0, 1, 2 or 3;
provided that the compound is not 2-chloro-N-(1,4-dihydro-2-oxo-2H-3,1-benzoxazin-7-yl)-5-[[(1-methylethyl)amino]sulfonyl]-benzamide; or
4-[2-oxo-7-(phenylmethoxy)-2H-1,3-benzoxazin-3(4H)-yl], Benzoic methyl ester.

2. The compound of claim 1 , wherein the compound is a compound of formula (la):

3. The compound of claim 1 , selected from:

4. A compound of formula (II):

or a pharmaceutically acceptable salt thereof, wherein:
X and Y are each independently selected from O and N-L-R 1 , wherein X is O and Y is N(-L-R 1 ) or X is N(-L-R 1 ) and Y is O;
Q is C(O), SO 2 , or —(CH 2 ) h —;
each L is independently selected from a bond, —C(O)—, —(CR a R b ) m —, —C(O)NR c — or —C(O)O—;
D and D 1 are each independently selected from a bond, O and NR c , provided that D and D 1 are not both a bond;
A is aryl or heteroaryl, each of which is substituted with 0-3 occurrences of R d ;
each R 1 is independently selected from hydrogen, C 1-4 alkyl, haloC 1-4 alkyl, alkyl-O-alkylene, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein each alkyl-O-alkylene, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl is substituted with 0-3 occurrences of R f and each alkyl and haloalkyl is substituted with 0-3 occurrences of R g ;
each R a and each R b are independently selected from hydrogen, C 1-4 alkyl, or R a and R b bound to the same carbon atom are taken together with the carbon atom to form a cycloalkyl;
each R c is independently selected from hydrogen and C 1-4 alkyl;
each R d is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, nitro, cyano, —OH and —O(C 1-4 alkyl), or two R d , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R f is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, nitro, cyano, —OH and —O(C 1-4 alkyl), or two R f , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R g is independently selected from nitro, cyano, —OH, —O(C 1-4 alkyl) or two R g , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R 2 is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy and hydroxyl;
h is 1, 2 or 3;
each m is independently 1, 2 or 3; and
each n is independently 0, 1, 2 or 3; provided that
1) D-Q-D 1 -A is not i) O-benzyl, ii) NHSO 2 -2-thiophenyl, iii) NHC(O)-optionally substituted phenyl, or iv) NHSO 2 -optionally substituted phenyl; and
2) the compound is not:
i) N-[2-[[[(1S)-2-cyclohexyl-1-methylethyl]amino]methyl]phenyl]-1,4-dihydro-2-oxo-2H-3,1-Benzoxazine-6-sulfonamide; or
ii) N-[2-[[[(1S)-2-cyclopentyl-1-methylethyl]amino]methyl]phenyl]-1,4-dihydro-2-oxo-2H-3,1-Benzoxazine-6-sulfonamide.

5. The compound of claim 4 , wherein the compound is a compound of formula (IIa):

6. The compound of claim 4 , selected from:

7. A compound of formula (IIIa):

or a pharmaceutically acceptable salt thereof, wherein:
X is O and Y is N(-L-R 1 ), or X is N(-L-R 1 ) and Y is O;
L 1 and L 2 are each independently selected from a bond, —O—, C(O)—, —C(O)O—, —OC(O)—, —C(O)NR c —, —NR c C(O)—, —S—, —SO— and —SO 2 —;
A is aryl or heteroaryl, each of which is substituted with 0-3 occurrences of R f ;
each R 1 is independently selected from hydrogen or C 1-4 alkyl, wherein each C 1-4 alkyl is substituted with 0-3 occurrences of R f ;
R a and R b are each independently selected from hydrogen, C 1-4 alkyl, haloC 1-4 alkyl, alkyl-O-alkylene, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein each alkyl-O-alkylene, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl is substituted with 0-3 occurrences of R f and each alkyl and haloalkyl is substituted with 0-3 occurrences of R g ; or
one of R a or R b is taken together with R 1 and the atoms to which they are respectively attached to form an optionally substituted five-membered heterocylyl;
each R c is independently selected from hydrogen and C 1-4 alkyl;
each R f is independently selected from halo, halo C 1-4 alkyl, C 1-4 alkyl, nitro, cyano, —OH and —O(C 1-4 alkyl), or two R f , attached to the same or adjacent carbon atoms, taken together with the atoms to which they are attached form an optionally substituted heterocyclyl;
each R g is independently selected from nitro, cyano, —OH, —O(C 1-4 alkyl) or two R g , attached to the same or adjacent

Assignees

• Salituro Francesco G
• Saunders Jeffrey O
• Agios Pharmaceuticals Inc

Inventors

• Salituro Francesco G
• Saunders Jeffrey O

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D265/18

  with hetero atoms directly attached in position 2 · CPC title

• C07D413/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D265/36 Primary

  condensed with one six-membered ring · CPC title